Correspondence 0001683168-23-008983 from CNS Pharmaceuticals, Inc. (CNSP)
CNS Pharmaceuticals, Inc.
Date: Dec. 20, 2023 · CIK: 0001729427 · Accession: 0001683168-23-008983
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-275973
Letter
CNS Pharmaceuticals, Inc.
2100 West Loop South, Suite 900
Houston, TX 77027
December 20, 2023
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Re: CNS Pharmaceuticals, Inc.
Registration Statement on Form S-1 (the “Registration Statement”)
File No. 333-275973
Reference is made to our letter, filed as correspondence with the U.S. Securities and Exchange Commission via EDGAR on December 14, 2023 regarding the acceleration of the effectiveness of the above-referenced Registration Statement to 5:00 P.M. (Eastern Time) on December 20, 2023. We hereby formally withdraw our prior request for acceleration of the effective date of such Registration Statement.
Very truly yours,
CNS Pharmaceuticals, Inc.
Show Raw Text
CORRESP
1
filename1.htm
CNS Pharmaceuticals, Inc.
2100 West Loop South, Suite 900
Houston, TX 77027
December 20, 2023
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Re: CNS Pharmaceuticals, Inc.
Registration Statement
on Form S-1 (the “Registration Statement”)
File No. 333-275973
Reference is made to our letter, filed as correspondence
with the U.S. Securities and Exchange Commission via EDGAR on December 14, 2023 regarding the acceleration of the effectiveness of the
above-referenced Registration Statement to 5:00 P.M. (Eastern Time) on December 20, 2023. We hereby formally withdraw our prior request
for acceleration of the effective date of such Registration Statement.
Very truly yours,
CNS Pharmaceuticals, Inc.
By: /s/ Christopher Downs
Name: Christopher Downs
Title: Chief Financial Officer
cc: Cavas Pavri, ArentFox Schiff LLP